BR100 Increased By (0.49%)
BR30 Increased By (0.14%)
KSE100 Increased By (0.45%)
KSE30 Increased By (0.43%)
AGHA 7.76 Increased By ▲ 0.01 (0.13%)
BECO 5.19 No Change ▼ 0.00 (0%)
BML 57.42 Decreased By ▼ -1.24 (-2.11%)
BOP 34.15 Increased By ▲ 0.46 (1.37%)
CNERGY 10.46 Decreased By ▼ -0.15 (-1.41%)
CSIL 5.42 Increased By ▲ 0.12 (2.26%)
FCCL 54.82 Increased By ▲ 1.08 (2.01%)
FFL 16.71 Increased By ▲ 0.25 (1.52%)
FNEL 1.25 Increased By ▲ 0.03 (2.46%)
KEL 7.42 Increased By ▲ 0.14 (1.92%)
KOSM 5.76 Increased By ▲ 0.12 (2.13%)
LOTCHEM 29.50 Decreased By ▼ -0.15 (-0.51%)
MLCF 95.49 Decreased By ▼ -0.87 (-0.9%)
NBP 203.51 Decreased By ▼ -0.02 (-0.01%)
NCPL 57.96 Increased By ▲ 1.11 (1.95%)
NPL 68.89 Increased By ▲ 1.58 (2.35%)
OGDC 317.39 Decreased By ▼ -0.83 (-0.26%)
PACE 10.74 Increased By ▲ 0.11 (1.03%)
PAEL 42.81 Increased By ▲ 1.04 (2.49%)
PIBTL 16.84 Increased By ▲ 0.03 (0.18%)
PPL 220.99 Increased By ▲ 0.82 (0.37%)
PRL 50.73 Increased By ▲ 1.68 (3.43%)
PTC 70.69 Increased By ▲ 0.68 (0.97%)
SSGC 28.20 Decreased By ▼ -0.94 (-3.23%)
TBL 9.84 Increased By ▲ 0.07 (0.72%)
TELE 8.85 Increased By ▲ 0.03 (0.34%)
TPL 18.32 Increased By ▲ 1.15 (6.7%)
TPLP 12.90 Increased By ▲ 0.39 (3.12%)
TREET 22.79 Increased By ▲ 0.20 (0.89%)
TRG 59.92 Decreased By ▼ -0.30 (-0.5%)
Business & Finance

Moderna to deliver 25 million COVID-19 vaccine doses to Australia

  • It has been trying to speed up the rollout of jabs after it was stalled by supply hold-ups in Europe and concerns about blood clots tied to the AstraZeneca shot.
  • The deal also includes the supply of 15 million doses of Moderna's updated variant booster vaccine candidate to be delivered in 2022, the company said.
Published Updated
By

Moderna Inc will supply Australia 25 million doses of its COVID-19 vaccine, of which 10 million doses against the original strain of the virus will be delivered this year, the drugmaker said on Wednesday.

Australia currently has two authorized vaccines from Pfizer-BioNTech and AstraZeneca.

It has been trying to speed up the rollout of jabs after it was stalled by supply hold-ups in Europe and concerns about blood clots tied to the AstraZeneca shot.

The deal also includes the supply of 15 million doses of Moderna's updated variant booster vaccine candidate to be delivered in 2022, the company said.

The pact with Moderna is subject to regulatory approval of its vaccine candidate, which is authorized for emergency use in individuals 18 years of age or older in the United States.

Moderna has also received authorization for its vaccine from health agencies including Canada, Israel, the European Union, the United Kingdom and Switzerland.

Comments

Comments are closed for this article.